Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables: 2023-2025

Historic Receivables for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to $5.1 million.

  • Tonix Pharmaceuticals Holding's Receivables fell 16.25% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year decrease of 10.75%. This contributed to the annual value of $4.6 million for FY2024, which is 49.50% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Receivables stood at $5.1 million, which was up 18.50% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Receivables ranged from a high of $9.2 million in Q4 2023 and a low of $2.3 million during Q3 2023.
  • Its 3-year average for Receivables is $5.0 million, with a median of $4.6 million in 2024.
  • Over the last 5 years, Tonix Pharmaceuticals Holding's Receivables had its largest YoY gain of 165.00% in 2024, and its largest YoY loss of 49.50% in 2024.
  • Tonix Pharmaceuticals Holding's Receivables (Quarterly) stood at $9.2 million in 2023, then plummeted by 49.50% to $4.6 million in 2024, then fell by 16.25% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q3 2025, $4.3 million for Q2 2025, and $4.6 million during Q1 2025.